The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2023

Filed:

Jan. 06, 2017
Applicants:

Paul N. Durfee, Albuquerque, NM (US);

Charles Jeffrey Brinker, Albuquerque, NM (US);

Yu-shen Lin, Seattle, WA (US);

Hon Leong, London, CA;

Inventors:

Paul N. Durfee, Albuquerque, NM (US);

Charles Jeffrey Brinker, Albuquerque, NM (US);

Yu-Shen Lin, Seattle, WA (US);

Hon Leong, London, CA;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/54 (2017.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); A61K 9/16 (2006.01); B82Y 5/00 (2011.01); A61K 47/69 (2017.01); C12N 15/88 (2006.01); A61K 47/10 (2017.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 47/548 (2017.08); A61K 9/16 (2013.01); A61K 9/5115 (2013.01); A61K 9/5123 (2013.01); A61K 9/5192 (2013.01); A61K 47/10 (2013.01); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); C12N 15/88 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01); B82Y 5/00 (2013.01);
Abstract

The present disclosure is directed to protocells or nanoparticles, which are optionally coated with a lipid bilayer, which can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and/or diagnosis of bone cancer, often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate cancer, breast cancer, lung cancer and ovarian cancer, among numerous others. These protocells or nanoparticles target bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and/or diagnostic agents for purposes of treating, diagnosing and/or monitoring the therapy of the bone cancer. Osteotropic protocells or nanoparticles, pharmaceutical compositions comprising a population of osteotropic protocells or nanoparticles and methods of diagnosing, treating and/or monitoring therapy of bone cancer are representative aspects.


Find Patent Forward Citations

Loading…